Soria J, Soria C
Laboratoire de Recherches Sainte-Marie, Hôtel Dieu, Paris.
J Mal Vasc. 1989;14 Suppl A:25-8.
Recent epidemiological studies have shown that an increase in fibrinogen level (even a slight increase) is an important risk factor for vascular disease. Consequently, drugs which induce a decrease in fibrinogen are of great importance. Pentoxifylline given in patients with vascular disease or in those with high risk of thrombosis (diabetes, arteritis) induces a significant decrease in plasma fibrinogen level. Furthermore, in patients with arteritis, the decrease in fibrinogen level after pentoxifylline is correlated with the improvement in the walking distance. Several hypotheses may be taken into account to explain the decrease in fibrinogen induced by pentoxifylline. The hypothesis based upon a decrease of fibrinogen synthesis seems very fascinating since pentoxifylline, inducing a decrease in Interleukin 1 activity on leukocytes, might be responsible also for a decrease in interleukin 1 activity as fibrinogen stimulating factor. Furthermore, the effect of pentoxifylline on fibrinolysis, reported by some authors, is also of importance for the prevention of thrombotic disorder.
最近的流行病学研究表明,纤维蛋白原水平升高(即使是轻微升高)是血管疾病的重要危险因素。因此,能使纤维蛋白原水平降低的药物非常重要。己酮可可碱应用于血管疾病患者或血栓形成高危患者(糖尿病、动脉炎)时,可使血浆纤维蛋白原水平显著降低。此外,在动脉炎患者中,己酮可可碱治疗后纤维蛋白原水平的降低与步行距离的改善相关。可以考虑几种假说来解释己酮可可碱引起的纤维蛋白原降低。基于纤维蛋白原合成减少的假说似乎很有吸引力,因为己酮可可碱可降低白细胞上白细胞介素1的活性,它可能作为纤维蛋白原刺激因子导致白细胞介素1活性降低。此外,一些作者报道的己酮可可碱对纤维蛋白溶解的作用,对预防血栓形成紊乱也很重要。